申请人:BLACKTHORN THERAPEUTICS INC
公开号:WO2021127459A1
公开(公告)日:2021-06-24
Compounds are provided that modulate the GPR139 receptor, compositions containing the same, and to methods of their preparation and use for treatment of a malcondition wherein modulation of the GPR139 receptor is medically indicated or beneficial. Such compounds have the structure of Formula (I): or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein R1, R4, R5, R9, R10, Q6, Q7, and Q12 are as defined herein.
提供了调节GPR139受体的化合物,含有这些化合物的组合物,以及它们的制备和用于治疗GPR139受体调节在医学上指示或有益的疾病的方法。这些化合物具有以下结构的化学式(I):或其药学上可接受的异构体、拉克酸盐、水合物、溶剂化合物、同位素或盐,其中R1、R4、R5、R9、R10、Q6、Q7和Q12如本文所定义。